Epithelial-mesenchymal transformation (EMT) occurs during both development and tumorigenesis. Transforming growth factor beta (TGFh) ligands signal EMT in the atrioventricular (AV) cushion of the developing heart, a critical step in valve formation. TGFh signals through a complex of type I and type II receptors. Several type I receptors exist although activin receptor-like kinase (ALK) 5 mediates the majority of TGFh signaling. Here, we demonstrate that ALK2 is sufficient to induce EMT in the heart. Both ALK2 and ALK5 are expressed throughout the heart with ALK2 expressed abundantly in endocardial cells of the outflow tract (OFT), ventricle, and AV cushion. Misexpression of constitutively active (ca) ALK2 in non-transforming ventricular endocardial cells induced EMT, while caALK5 did not, thus demonstrating that ALK2 activity alone is sufficient to stimulate EMT. Smad6, an inhibitor of Smad signaling downstream of ALK2, but not ALK5, inhibited EMT in AV cushion endocardial cells. These data suggest that ALK2 activation may stimulate EMT in the AV cushion and that Smad6 may act downstream of ALK2 to negatively regulate EMT. D
Introduction
Transforming growth factor beta (TGFh) mediates processes as diverse as development, wound healing, and tumor progression (Grazul-Bilska et al., 2003; Waite and Eng, 2003) . TGFh signaling occurs through the liganddependent formation of a heteromeric complex of type I and type II receptors. Both receptors contain a serine/threonine kinase domain. The constitutively active kinase domain of the type II receptor phosphorylates the type I receptor in the GS box leading to activation of the type I receptor kinase domain. Once activated, the type I receptor phosphorylates downstream signaling molecules including members of the Smads family of transcription factors (Kretzschmar and Massague, 1998) . The type I receptor activin receptor-like kinase (ALK) 5 mediates several TGFh-induced responses. In the presence of TGFh, ALK5 associates with the type II TGFh receptor (TBRII) to stimulate PAI-1 expression or growth arrest (Bassing et al., 1994; ten Dijke et al., 1994a; Wrana et al., 1994) , establishing ALK5 as the prototypic type I TGFh receptor.
A second type I receptor, ALK2, interacts with TBRII as well as activin and bone morphogenetic protein (BMP) type II receptors in the presence of their respective ligands (Attisano et al., 1993; Ebner et al., 1993a Ebner et al., ,b, 1994b Yamashita et al., 1995) . Despite potentially signaling through TGFh, activin, and BMP ligands ALK2 activation has thus far only been demonstrated downstream of BMP7 binding to activin type II receptors (Macias-Silva et al., 1998) . However, data suggest that ALK2 signals down-stream of ligands other than BMP7 since alk2 null mice die early in gastrulation (Gu et al., 1999) while Bmp7 null mice survive until soon after birth (Dudley et al., 1995; Luo et al., 1995) . ALK2 has been proposed to mediate epithelial-mesenchymal transformation (EMT) in response to TGFh in cultured mammary epithelial cells (Miettinen et al., 1994) . This observation suggested that TGFh ligands may signal through ALK2 and that ALK2 may potentially mediate EMT in other cell types. However, efforts to confirm this observation have been unsuccessful (Piek et al., 1999) .
We used explanted chick atrioventricular (AV) cushions as a model system to identify potential roles for ALK2 and ALK5 during EMT. EMT in the AV cushion is a critical step in valve formation that occurs early in heart development. During EMT, the heart is a simple tube composed of two concentric layers of epithelia separated by an acellular region of extracellular matrix termed the cardiac jelly. In both the AV cushion and outflow tract (OFT), cells from the inner endocardial layer transform into mesenchyme and invade the cardiac jelly where they later contribute to the connective tissue of the valves and membranous septa of the adult heart (Lamers et al., 1995; Sadler, 1985) . During EMT, cells first undergo an activation step in which they lose their cell-cell contacts and change shape from polygonal epithelial cells to elongated mesenchymal cells. Subsequently, these activated cells invade and migrate through the cardiac jelly to complete the transformation process. Studies have shown that these steps occur in AV cushions, but not ventricles, both in situ and using an in vitro model in which explants are placed on collagen gels (Bernanke and Markwald, 1982) . To identify potential roles for candidate molecules in EMT, ventricular or AV cushion explants can be used to score for gain or loss of function, respectively, as we previously reported (Brown et al., 1999) . In the AV cushion, EMT is dependent on soluble factors derived from the outer myocardial cell layer that reach the endocardium prior to EMT (Krug et al., 1985) . In collagen gel explants, exogenous TGFh ligands support both the epithelial cell activation and mesenchymal cell migration that constitute EMT in the developing chick AV cushion Potts and Runyan, 1989; Ramsdell and Markwald, 1997) .
Prior studies in our laboratory demonstrated that ALK2 antisera, but not ALK5 antisera, inhibited EMT in the AV cushion (Lai et al., 2000) . This experiment suggested a requirement for ALK2 during EMT, but did not address whether ALK2 was sufficient to induce transformation. Also, these experiments could not differentiate between the effects of the antisera on the endocardium versus the myocardium. To address these issues, we tested whether the activity of ALK2 or ALK5 is sufficient to induce EMT in ventricular endocardial cells. We demonstrate that constitutively active (ca) ALK2, but not caALK5, stimulates normally non-transforming ventricular endocardial cells to undergo EMT. In AV cushion endocardial cells, overexpression of Smad6, an inhibitor of ALK2 Smad signaling, decreased EMT consistent with a role for ALK2 and demonstrating that EMT is Smad-dependent. These data, together with the abundant expression of ALK2 mRNA in the endocardium of the OFT, ventricle, and AV cushion are consistent with a physiological role for this receptor in mediating EMT in the heart, and perhaps other organ systems.
Materials and methods

In situ hybridization
Performed as previously described (Barnett et al., 1994) with the substitution of 33 P for 35 S at N2 Â 10 4 cpm/Al. Probes were as follows: chicken ALK2 (GenBank Accession # U38622; nt 245-468) and chicken ALK5 (GenBank Accession # D14460; nt 184-468).
Alkaline phosphatase assay
C3H10T1/2 cells were split at a density of 5 Â 10 4 cells/ well in a 24-well dish. Immediately after splitting, cells were transiently transfected with 400 ng of plasmid containing lacZ (PVR h-Gal) using Fugene 6 transfection reagent (Roche) and infected with adenovirus encoding either Green Fluorescent Protein (GFP) alone, caALK2, or caALK5. Twenty-four hours later, the medium was removed and replaced with DMEM, 0.2% FBS and vehicle or 1 Ag/ml BMP2 was added. After 24 h, the cells were lysed with 10 mM Tris pH 7.5, 50 mM sodium acetate, 0.2 mM EDTA, 1% Triton X-100 for 30 min at 48C. Half of the lysate was added to 1-step PNPP soluble alkaline phosphatase substrate (Pierce) and incubated overnight at room temperature. Alkaline phosphatase activity was measured by reading the A405 nm. The other half of the lysate was added to ONPG soluble h-galactosidase substrate (Pierce) to normalize the samples to h-galactosidase activity. Samples were incubated overnight at 308C and the A405 nm was measured.
Luciferase assays
C3H10T1/2 cells were plated into 12-well dishes at 1 Â 10 5 cells/well. Cells in each well were transiently transfected with 0.8 Ag of p3TP-Lux and 8 ng of a Renilla luciferase plasmid (Promega) for normalization. Immediately after transfection, the cells were infected with adenovirus containing either GFP alone, caALK2, or caALK5. Twenty-four hours after transfection, the cells were incubated in DMEM supplemented with 0.2% FBS. Cells were harvested 24 h later and assayed for luciferase activity (Promega Luciferase Assay System). Total light emission was measured during the initial 10 s of the reaction using a Turner Designs TD-20/20 Luminometer.
Construction of adenoviruses and viral titer
Adenoviruses were generated using the pAdEasy system (He et al., 1998) . All concentrated viruses were titered by performing serial dilutions of the concentrated virus and counting the number of GFP-expressing 293 cells after 18-24 h. Both the lacZ and mouse Smad6 adenoviruses were generated by homologous recombination in 293 cells. These viruses do not co-express GFP and therefore were titered using the Takara Assay (Takara Shuzo Co., Ltd.).
Viral injections and collagen gel assays
Stage 10-12 chick embryos were harvested onto Whatman paper rings and immediately injected with adenovirus in the heart lumen. Injections were performed using 20-50 pulses, approximately 50 ms each, delivered by a picospritzer. Fast Green Dye (Sigma) was used to monitor injection of the virus. Immediately after injection, the embryos were placed on egg agar and incubated at 398C. After 24 h, ventricular or AV cushion explants were excised from the infected hearts and placed in culture as described previously (Brown et al., 1996) . After 48 h, the explants were fixed in 0.8% formaldehyde, 0.05% glutaraldehyde. GFP expression by virally infected cells was observed on an inverted fluorescent microscope. The phenotype of each GFP-expressing cell was determined and scored as epithelial, activated, or transformed as described in Results. The number of ventricular explants examined and cells in each category were as follows: caALK2 adenovirus (n = 59; total number of cells, 1836; epithelial, 331; activated, 1051; transformed, 454), n = number of explants, GFP control adenovirus (n = 54; total number of cells, 937; epithelial, 584; activated, 223; transformed, 130), caALK5 adenovirus (n = 71; total number of cells, 2566; epithelial, 1752; activated, 576; transformed, 238) , GFP control adenovirus (n = 75; total number of cells, 1359; epithelial, 827; activated, 360; transformed, 172) . The number of AV cushion explants examined and cells in each category were as follows: caALK5 adenovirus (n = 41; total number of cells, 2061; epithelial, 1074; activated, 552; transformed, 435) . GFP control adenovirus (n = 35; total number of cells, 1051; epithelial, 538; activated, 280; transformed, 233), caALK2 adenovirus (n = 48; total number of cells, 1976; epithelial, 682; activated, 743; transformed, 551) . GFP control adenovirus (n = 51; total number of cells, 3758; epithelial, 1486; activated, 1152; transformed, 1120) .
AV cushion explants infected with either lacZ or Smad6 adenoviruses were scored for the total number of transformed cells by optically sectioning the collagen gels using Hoffman Optics. The number of explants in each group and the mean number of transformed cells F SEM, expressed as a percentage of control, were as follows: lacZ adenovirus (n = 54; 100 F 8%), Smad6 adenovirus (n = 48; 65 F 10%).
Results
ALK2 mRNA is abundantly expressed in the endocardium
We analyzed the expression patterns of both ALK2 and ALK5 by in situ hybridization in stage 14-19 embryonic chicken hearts (Hamburger and Hamilton, 1951) . These embryonic stages are inclusive of the initiation of EMT in both the AV cushion and OFT. The mRNA expression pattern for both of these receptors was invariant throughout the stages examined. While ALK2 mRNA expression was noted throughout the embryo, expression was particularly abundant in endothelial cells comprising the endocardium of the heart (Figs. 1A, B) . Expression of ALK2 was abundant in the OFT, ventricle, and AV cushion with a decrease in expression observed at the border between the AV cushion and the atria (Figs. 1E, F) and between the OFT and the beginning of the aortic sac (Figs. 1G, H). Notably, little expression of ALK2 mRNA was observed in endothelial cells outside of the heart such as in the dorsal aorta (Figs. 1A, B). The abundant endocardial expression of ALK2 contrasted sharply with the expression pattern of ALK5 mRNA. ALK5 is expressed at low levels throughout the embryo, including the endocardium (Figs. 1C, D) . These studies show endocardial expression of both ALK2 and ALK5 during EMT with notably high levels of ALK2 observed in the OFT, ventricle, and AV cushion compared to the rest of the embryo.
Constitutively active ALK2 and ALK5 are specific for their respective signaling pathways
The expression of both type I receptors in the heart prompted us to address the functional role of each during EMT. We reasoned that if ALK2 or ALK5 are sufficient to stimulate EMT in the heart, then the misexpression of constitutively active forms of these receptors in ventricular endocardial cells, which do not normally undergo EMT, should result in a gain of function. In mammalian type I receptors, single amino acid substitutions for an aspartate residue in a region known as the GS box have previously been demonstrated to render these receptors constitutively active (Macias-Silva et al., 1998; Wieser et al., 1995) . Using site-directed mutagenesis, we made similar mutations in chicken ALK2 and ALK5 and showed that these receptors were constitutively active (Ward et al., 2002) . We then generated adenoviruses that contained either caALK2 or caALK5 and GFP expressed by separate CMV promoters. Adenoviruses were tested for specificity in C3H10T1/2 cells that produce alkaline phosphatase in response to caALK2 or high doses of BMP2 (Fujii et al., 1999; Wang et al., 1993) . Cells were infected with adenoviruses containing either GFP alone, caALK2, or caALK5 and then either vehicle or 1 Ag/ml BMP2 was added. As expected, both BMP2 and caALK2 stimulated alkaline phosphatase production while caALK5 did not ( Fig. 2A) . This indicated that the constitutively active receptors maintained their specificity for their respective signaling pathways. To further test the specificity of our viruses, we transfected C3H10T1/2 cells with the p3TP-lux luciferase reporter plasmid, which is known to be activated by ALK5 (Bassing et al., 1994; Wieser et al., 1995) . Again, we infected cells with viruses containing GFP alone, caALK2, or caALK5. As predicted, caALK5 activated the p3TP-lux reporter approximately 5-fold while caALK2 had a smaller effect (Fig. 2B) . The 2-fold stimulation observed with caALK2 can be explained by the ability of Smad1, which is activated by caALK2, to stimulate the p3TP-lux reporter in some cell types (Liu et al., 1998) . These data demonstrate that each adenoviral construct encodes a constitutively active type I receptor with the predicted specificity.
Constitutively active ALK2 stimulates EMT in ventricular explants
To test whether caALK2 or caALK5 are sufficient to induce EMT, we took advantage of the fact that ventricular endocardial cells found adjacent to the AV cushion do not undergo EMT. We used adenoviruses to introduce these constitutively active receptors into ventricular endocardial cells and scored for gain of function. In order to infect endocardial cells prior to the initiation of EMT in the heart, we injected adenovirus into the lumen of stage 10-12 chick hearts. These stages occur prior to completion of the circulatory system and before the advent of a regular heart beat, thus increasing the dwell time in which the endocardial cells are exposed to the virus. We injected virus into the heart lumen at these early stages in an effort to efficiently infect endocardial cells and minimally infect the myocardium. After injection, we allowed the embryos to develop for 24 h prior to harvesting ventricular explants. The 24-h incubation period allowed most embryos to reach stage 14-15, when EMT begins in the AV cushion. Direct observation of embryos after injection revealed that embryos injected with any virus used were indistinguishable from uninjected control embryos. The majority of embryos demonstrate grossly normal heart and vascular development (Fig. 3A) and the heart continued to beat and move blood normally. Imaging of GFP in the intact embryo immediately prior to harvest showed efficient infection of endocardial cells in the heart (Fig. 3B) . Some embryos were harvested for sectioning and analysis. No gross abnormalities were noted (Fig.  3C) . Ventricular explants were only harvested from grossly normal embryos that developed to at least stage 14. The explants were placed on a collagen gel matrix for 48 h, fixed, and scored for GFP-expressing cells.
We observed a noticeable difference in the phenotype of explants infected with caALK2 virus compared to those infected with the GFP control virus. By inspection, ventricular explants infected with caALK2 adenovirus showed many elongated, fusiform cells on the gel surface and small or non-existent epithelial sheets (Fig. 4A) . In contrast, control explants exhibited endocardial cell monolayers on the gel surface with few if any elongated, fusiform cells present (Fig. 4A) . To quantify these differences in phenotype, GFP-expressing cells were scored morphologically as epithelial, activated, or transformed. We defined epithelial cells as rounded cells present on the gel surface in tightly packed sheets. Elongated or fusiform cells present on the surface of the gel with no cell to cell contacts we identified as activated. We defined transformed cells as those elongated cells that invaded the collagen matrix and thus had completed EMT. By quantifying the number of GFP-expressing cells in each category, we observed that caALK2 caused a significant increase in both activated and transformed cells with a concomitant decrease in the number of epithelial cells (Fig. 4B) . The morphology of caALK5 explants was identical to control explants and no alteration was noted among any of the cellular phenotypes examined (Fig. 4C ). These data demonstrate that ALK2, but not ALK5, is sufficient to induce EMT and suggest that native ALK2 in ventricular endothelial cells is not active in these normally non-transforming cells.
Since caALK5 had no effect in ventricular explants, we reasoned that caALK5 may have the opposite effect of caALK2 and negatively regulates EMT. To test this possibility, we infected AV cushion endothelial cells with caALK5 adenovirus and again scored GFP-expressing cells. We found that caALK5 had no effect on the ability of AV cushion endothelial cells to undergo EMT (Fig. 5A) . Overexpression of caALK2 in AV cushion endothelial cells results in a significant increase in the percentage of activated cells (Fig. 5B) which is also the cell phenotype where we see the most robust change in ventricular explants (Fig. 4B) . Changes in epithelial and transformed cells do not reach significance (Fig. 5B ). This is due to the fact that two endothelial cell populations are present in the AV cushion, those fated to transform and those that do not. Here, we are infecting both cell populations and any effect on the percentage of epithelial and transformed cells is obscured by the presence of normally transforming AV cushion endothelial cells that have been infected with virus. The complication introduced by the presence of two cell Photomicrograph of an embryo 24 h following injection. Heart and vascular development is indistinguishable from similarly treated uninjected embryos. (B) Immediately prior to explant harvest, imaging of GFP in a heart injected with adenovirus reveals abundant GFP expression in endocardial cells. White lines demarcate the position of the myocardium. (C) A section through the ventricle of a virally infected heart after 24 h of incubation reveals a lack of gross abnormalities in either the endocardium or myocardium. Note that virally infected cells, observed by GFP, are observed only in the endocardium. Paraffin embedding and sectioning was performed by standard methods (Brown et al., 1999) . Representative photographs are depicted in each case. M, myocardium; EC, endocardium. populations in the AV cushion is why we score for gain of function in the ventricle where a single, normally nontransforming cell population is found. However, these data in the AV cushion are consistent with stimulation of ALK2 moving endocardial cells from an epithelial to a mesenchymal phenotype. Further, the difference in magnitude of effect of caALK2 on ventricular versus AV cushion endothelial cells suggests that, although ALK2 is present in each, ALK2 is not normally active in ventricular endothelial cells, but is near maximally activated in AV cushion endothelial cells.
Smad6 overexpression decreases EMT in AV cushion explants
Smad6 is an inhibitor of Smad signaling downstream of ALK2, but does not affect ALK5 signaling (Hata et al., 1998; Macias-Silva et al., 1998) . Smad6 is expressed in AV cushion endocardial cells (Galvin et al., 2000; Yamada et al., 1999) and targeted deletion of Smad6 results in valvular hyperplasia that is postulated to be due to enhanced EMT or cell proliferation (Galvin et al., 2000; Yamada et al., 1999) . To directly test for a role of Smad6 in regulating EMT, we overexpressed Smad6 in AV cushion endocardial cells. The Smad6 adenovirus used was previously characterized and demonstrated to express functional Smad6 protein (McDonnell et al., 2001) . We injected either Smad6 adenovirus or a control adenovirus containing lacZ into the lumen of stage 10-12 chick hearts using a titer that infected approximately Fig. 5 . Effect of caALK5 and caALK2 on EMT in AV cushion endocardial cells. AV cushion explants were infected with adenovirus encoding GFP alone, caALK5, or caALK2. GFP-expressing cells were counted and scored as epithelial, activated, or transformed and the percent of the total GFPexpressing cells was calculated. Shown is the average percent of the total number of GFP-expressing cells for each category, calculated from 3 experiments. caALK5 had no effect on the percent of cells in each category. GFP: epithelial 50 F 6%; (mean F SD), activated 26 F 0.5%, transformed 23 F 6%. caALK5: epithelial 48 F 13%, activated 28 F 6%, transformed 23 F 7%. Two-tailed Student's t tests: epithelial P = 0.854, activated P = 0.680, transformed P = 1. caALK2 significantly increased the percentage of activated cells. GFP: epithelial 40 F 2%; (mean F SD), activated 31 F 2%, transformed 29 F 4%. caALK2: epithelial 34 F 4%, activated 38 F 1%, transformed 28 F 5%. Two-tailed Student's t tests: epithelial P = 0.161, activated P = 0.0289, transformed P = 0.840. (B) caALK2 induced statistically significant increases in both activated and transformed cells and a concomitant decrease in epithelial cells. GFP: epithelial 61 F 12%; (mean F SD), activated 25 F 8%, transformed 14 F 4%. caALK2: epithelial 18 F 2%, activated 57 F 5%, transformed 25 F 4%. Two-tailed Student's t tests: epithelial P = 0.008, activated P = 0.002, transformed P = 0.010 (TP b 0.01). (C) caALK5 produced no change in the percent of cells in each category. GFP: epithelial 61 F 1%, activated 27 F 3%, transformed 12 F 4%. caALK5: epithelial 67 F 9%, activated 23 F 6%, transformed 10 F 3%. Two-tailed Student's t tests: epithelial P = 0.342, activated P = 0.375, transformed P = 0.498. 30% of the endocardial cells. AV cushion explants harvested from the infected hearts were cultured for 48 h on collagen gels before quantifying the total number of cells that underwent EMT. Our findings show that Smad6 decreased the number of transformed cells by 35% compared to control (Fig. 6) . These data are consistent with a role for ALK2 activation in EMT and demonstrate that EMT in the AV cushion is Smad-dependent.
Discussion
TGFh is an important regulator of EMT in the heart, yet the type I receptor that mediates this effect is unknown. Our prior studies demonstrated that ALK2 antisera, but not ALK5 antisera blocked EMT, suggesting a requirement for ALK2 during transformation (Lai et al., 2000) . However, these studies could not address whether ALK2 was sufficient to induce EMT, or whether ALK2 mediated its effects through the endocardium or the myocardium. Here, we demonstrate that caALK2 is sufficient to stimulate EMT in the heart and that caALK5 is without effect. These results show that ALK2 directly stimulates EMT in endocardial cells. Surprisingly, caALK5 had no effect in ventricular explants and did not negatively regulate EMT in the AV cushion. Further, overexpression of Smad6 in AV cushion endocardial cells decreased EMT, thus supporting a role for ALK2 and demonstrating that EMT is Smad-dependent. These data suggest that the effects of TGFh in the heart are independent of the prototypical type I TGFh receptor ALK5, and instead, are mediated by ALK2 signaling through Smads.
We propose that ALK2 may signal EMT in response to TGFh ligands based on experiments in which exogenous TGFh supported both activation and transformation in AV cushion endocardial cells (Potts and Runyan, 1989; Potts et al., 1991) . Besides TGFh, ALK2 also binds BMPs and activins, though only binding of BMP7 to ALK2 has been demonstrated to result in activation of ALK2 kinase activity (Macias-Silva et al., 1998) . In the mouse, BMP7 is expressed throughout the myocardium (Dudley and Robertson, 1997; Solloway and Robertson, 1999) and at E12.5 is found in mesenchyme under the valve leaflets (Kim et al., 2001) . However, mice with a targeted deletion of Bmp7 lack cardiac defects (Dudley et al., 1995; Luo et al., 1995) . We found that addition of BMP7 to ventricular explants had no effect on EMT despite the presence of ALK2 (data not shown). This raises the question of whether and how ALK2 is activated in ventricular endothelial cells during cardiac development.
There is emerging evidence that TGFh signaling diversity may be associated with the differential coupling of TGFh to type I receptors other than ALK5. ALK1, the molecule most closely related to ALK2, was discovered to mediate TGFh-dependent responses during angiogenesis. Experiments in endothelial cells demonstrated that low concentrations of TGFh act via ALK1 to stimulate the endothelial cell migration and proliferation required for angiogenesis (Goumans et al., 2002) . Our laboratory is asking whether ALK2, like ALK1, mediates TGFh-dependent responses. We identified a role for ALK2 downstream of TGFh during development of the parasympathetic response in chick atrial myocytes (Ward et al., 2002) . Constitutively active ALK2 was found to reproduce the effects of TGFh on Ga i2 expression in 14 day in ovo (dio) atrial myocytes. In these same cells, TGFh stimulated the ALK5-unresponsive, ALK2-responsive pVent luciferase reporter. In the present study, we demonstrate that ALK2 is sufficient to stimulate a TGFh-dependent EMT in the AV cushion whereas we have been unable to identify a role for ALK5. These data support the hypothesis that ALK2 may mediate TGFh signaling.
The differential expression of ALK2 may represent a mechanism for specifying cellular responsiveness to TGFh. We observed abundant expression of ALK2 mRNA in endocardial cells of the OFT, ventricle, and AV cushion, but not in extra-cardiac endothelial cells. Differential expression of ALK1 has also been noted in endothelial cells. ALK1 levels were observed to be significantly higher in the endothelium of arterioles compared with venous endothelial cells (Goumans et al., 2002) . It is tempting to speculate that the localized expression of high levels of ALK2 mRNA in the endocardium of the developing heart affects coupling of TGFh signals to ALK2 instead of ALK5. Our examination of the development of the parasympathetic response in atrial myocytes demonstrated that TGFh activation of the pVentluc reporter correlated with an increase in ALK2 expression. Increased levels of ALK2 compared to ALK5 caused TGFh signaling to apparently switch from ALK5 in 5 dio atrial myocytes to ALK2 in 14 dio cells. This suggests that the stoichiometry between ALK2 and ALK5 may determine which type I receptor mediates the effects of TGFh in a given cell.
Other TGFh receptors may also influence which type I receptor is recruited to the signaling complex. Prior studies in our laboratory demonstrated that neutralizing antisera against TBRII or TBRIII blocked endocardial cell activation and subsequent transformation in the AV cushion (Brown et al., 1996 (Brown et al., , 1999 . Further, misexpression of TBRIII in the ventricle and addition of TGFh2 results in EMT in nontransforming ventricular endocardial cells (Brown et al., 1999) . Demonstration of a requirement for TBRII and TBRIII during EMT, and co-localization of these receptors in AV cushion endothelial cells, led us to propose that a complex of at least TBRII and TBRIII mediates EMT in the AV cushion. The current model of TGFh signal transduction presupposes that a type I receptor is an essential component of the signal transduction complex. Data presented here, and prior studies using neutralizing antisera to ALK2 and ALK5 (Lai et al., 2000) , suggest that ALK2 is the type I receptor required for EMT in the AV cushion and not ALK5. Based on these results, we suggest that a complex of ALK2, TBRII, and TBRIII mediates EMT in the AV cushion in response to TGFh ligands. TBRIII is expressed in endothelial cells lining the AV and OFT cushions which are a subset of endothelial cells that abundantly express ALK2. This overlapping expression of TBRIII and ALK2 may be required for ALK2 activation and may explain why AV endothelial cells undergo EMT and ventricular endothelial cells do not. A precedent for an interaction between TBRIII and ALK2 exists with regards to the two most related molecules, endoglin and ALK1, respectively. The demonstration that mutations in either endoglin (McAllister et al., 1994) or ALK1 (Johnson et al., 1996) result in hereditary hemorrhagic telangiectasia provides genetic evidence that endoglin and ALK1 lie in the same or parallel pathways to regulate blood vessel morphology. Lux et al. (1999) demonstrated a direct association of ALK1 with endoglin and that TGFh addition activated ALK1 signaling. These data suggest that endoglin modulates TGFh signaling by activating type I receptors other than ALK5. We hypothesize a similar role for TBRIII, which may influence downstream signaling by recruiting ALK2 to the signaling complex instead of ALK5. Smad6 may function as an endogenous regulator of EMT in the heart. In support of this, Smad6 mRNA is expressed in the developing heart during EMT and is especially abundant in the OFT and AV cushion in both chick and mouse (Galvin et al., 2000; Yamada et al., 1999) . Further, mice homozygous null for Madh6 (which encodes the Smad6 protein) develop valvular hyperplasia that the authors propose may be caused by enhanced EMT or mesenchymal cell proliferation in the endocardial cushions (Galvin et al., 2000) . Our experiments tested the effects of Smad6 on EMT directly. We found that overexpression of Smad6 decreased EMT in the AV cushion, supporting a role for Smad6 as a negative regulator of EMT. We have demonstrated here that ALK2 is sufficient to induce EMT. Work from other laboratories has shown that Smad1, 5, and 8 are downstream of ALK2, whereas ALK5 signals through Smad2 and 3 (Chen and Massague, 1999; Chen et al., 1997; Macias-Silva et al., 1998; Nakao et al., 1997) . Since Smad6 is a selective antagonist of Smad1 signaling (Hata et al., 1998) , it would be expected to inhibit ALK2 signaling through Smads. Although we cannot exclude the possibility that ALK2 and Smad6 are in parallel pathways that regulate EMT, we propose that Smad6 negatively regulates EMT by inhibiting ALK2 signaling. Therefore, Smad6 may act endogenously to regulate the number of cells that undergo EMT, and thereby regulate valvulogenesis, by inhibiting Smad signaling downstream of ALK2.
ALK2 and Smad6 regulation of EMT during valvulogenesis implicates these two molecules in congenital heart disease. Occurring at a rate of nearly 1 in 100 live births, congenital heart disease is a common problem that often includes valve malformations (Hoffman, 1990; Hoffman and Kaplan, 2002) . Outside of the heart, EMT is an important process throughout development and tumor progression. The determination of other examples of EMT that involve ALK2 and Smad6, and the identification of factors that favor ALK2 over ALK5 signaling, are likely to yield novel insight into the causes of congenital defects and tumorigenesis.
